The FDA approved a new treatment for age related macular degeneration called Eylea (Aflibercept) of Regeneron Pharmaceuticals Inc.
Macular degeneration is one of the most common cause of blindness, rapid decline of sharp vision among older in American. Through many efforts and studies, now there will be a medication treatment for the particular cases.
How does Eylea work and get the approval from PDA?
Prior treatment is for wet age-related macular degeneration. In this form, there is abnormal growth of blood vessels that can leak fluid into the macula, leading to vision loss. The participant’s vision performs a positive change.
Specifically, the before image shows white where blood vessels were leaking fluid into his macula while the after image shows what happened after the drug did its work soaking up molecules, said Dr Alexander Eaton who played a part in the approval for the medical breakthrough. The most significant improvement with Eylea is the patient can go longer between treatments, added he.
Eylea will cost about $1,850 per dose or $16,000 for a year’s treatment, said Robert Terifay, senior vice president for commercial, during a conference call. The drug will be available for doctors to order Nov. 21 and delivered by the next day, he said.
For more information about this drug approval, go to: www.bloomberg.com/news/2011-11-19/regeneron-wins-fda-approval-for-blindness-drug-eylea/